Sunesis Pharmaceuticals with ticker code (SNSS) now have 3 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 12 and 1.5 with a mean TP of 6.17. Now with the previous closing price of 3.56 this is indicating there is a potential upside of 73.3%. There is a 50 day moving average of 2.98 and the 200 day MA is 2.02. The company has a market capitalisation of $78m. Visit the company website at: http://www.sunesis.com
Sunesis Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton’s tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals was founded in 1998 and is headquartered in South San Francisco, California.